Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Receivables: 2014-2018

Historic Receivables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 5 years, with Dec 2018 value amounting to $24,000.

  • Viridian Therapeutics, Inc.\DE's Receivables rose 2494.74% to $1.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $1.8 million, marking a year-over-year increase of 38.82%. This contributed to the annual value of $24,000 for FY2018, which is 99.06% down from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Receivables stood at $24,000 for FY2018, which was down 99.06% from $2.6 million recorded in FY2017.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Receivables ranged from a high of $2.6 million in FY2017 and a low of $24,000 during FY2018.
  • Its 3-year average for Receivables is $966,667, with a median of $320,000 in 2016.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Receivables skyrocketed by 698.75% in 2017 and then plummeted by 99.06% in 2018.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Receivables stood at $1.1 million in 2014, then crashed by 63.79% to $394,000 in 2015, then fell by 18.78% to $320,000 in 2016, then surged by 698.75% to $2.6 million in 2017, then plummeted by 99.06% to $24,000 in 2018.